中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
6期
1063-1064,1065
,共3页
刘遂库%史海贤%门利玲%刘清%吴玉霞
劉遂庫%史海賢%門利玲%劉清%吳玉霞
류수고%사해현%문리령%류청%오옥하
右美托咪定%阿片类药物%舒芬太尼%芬太尼%布托啡诺%联合用药%稳定性
右美託咪定%阿片類藥物%舒芬太尼%芬太尼%佈託啡諾%聯閤用藥%穩定性
우미탁미정%아편류약물%서분태니%분태니%포탁배낙%연합용약%은정성
Dexmedetomidine%Opioid drugs%Sufentanil%Fentanil%Butorphanol%Drug combination%Stability
目的：：研究右美托咪定分别与3种阿片类药物(舒芬太尼、芬太尼和布托啡诺)联合用药时的稳定性,以供临床合理用药参考。方法：右美托咪定分别与阿片类药物舒芬太尼、芬太尼及布托啡诺配伍,配制在0.9%氯化钠注射液中,室温放置,在0,24,48和96 h分别取样,进行性状、pH、不溶性微粒检查,并进行质谱检测。结果：在96 h内,配伍溶液均澄清透明,pH稳定,不溶性微粒检查符合规定,质谱检测显示无新物质生成。结论：3种配伍用药方案安全、合理、具有临床可行性。
目的：：研究右美託咪定分彆與3種阿片類藥物(舒芬太尼、芬太尼和佈託啡諾)聯閤用藥時的穩定性,以供臨床閤理用藥參攷。方法：右美託咪定分彆與阿片類藥物舒芬太尼、芬太尼及佈託啡諾配伍,配製在0.9%氯化鈉註射液中,室溫放置,在0,24,48和96 h分彆取樣,進行性狀、pH、不溶性微粒檢查,併進行質譜檢測。結果：在96 h內,配伍溶液均澄清透明,pH穩定,不溶性微粒檢查符閤規定,質譜檢測顯示無新物質生成。結論：3種配伍用藥方案安全、閤理、具有臨床可行性。
목적：：연구우미탁미정분별여3충아편류약물(서분태니、분태니화포탁배낙)연합용약시적은정성,이공림상합리용약삼고。방법：우미탁미정분별여아편류약물서분태니、분태니급포탁배낙배오,배제재0.9%록화납주사액중,실온방치,재0,24,48화96 h분별취양,진행성상、pH、불용성미립검사,병진행질보검측。결과：재96 h내,배오용액균징청투명,pH은정,불용성미립검사부합규정,질보검측현시무신물질생성。결론：3충배오용약방안안전、합리、구유림상가행성。
Objective:To study the stability of dexmedetomidine combined with three opioid drugs ( sufentanil, fentanil and butor-phanol) in order to guide the reasonable clinical prescription. Methods:Dexmedetomidine was respectively combined with sufentanil, fentanil and butorphanol in 0. 9% sodium chloride injection. The mixture was stored at room temperature for 0, 24, 48 and 96h, and then withdrawn for the detection of appearance, pH value, insoluble particles, and the analysis of mass spectrometry was performed. Results:Within 96 h, the prepared solutions were clear and transparent with stable pH value and qualified insoluble particles, and the results of mass spectrometry showed no new substance was generated. Conclusion:The three combination schemes are safe, reasonable and feasible in clinical application.
